Denosumab marks Accord’s sixth biosimilar approval in Europe. The CHMP has issued a positive opinion for Denosumab, to be marketed as Osvyrti® and Jubereq®. Osvyrti® is Accord’s second osteoporosis biosimilar, following Sondelbay®. The CHMP’s endorsement paves the way for market…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.